Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532734 · ClinicalTrials.gov registry record
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
A clinical trial of Esophageal Adenocarcinoma and Eating Disorders, sponsored by Denver Health and Hospital Authority.
- Recruiting
- Registry status
- 25
- Enrollment target
- 3
- Study locations
NCT06532734: Recruiting study of Esophageal Adenocarcinoma and Eating Disorders, sponsored by Denver Health and Hospital Authority.
NCT06532734 is a study of Esophageal Adenocarcinoma and Eating Disorders that is actively recruiting participants, run by Denver Health and Hospital Authority. The registered enrollment target is 25 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06532734, a study of Esophageal Adenocarcinoma and Eating Disorders, is actively recruiting participants, sponsored by Denver Health and Hospital Authority.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors
Primary Outcome
Individuals with severe forms of eating disorders with purging and ruminating behaviors not meeting a current screening guidelines for BE will test positive for BE
Conditions Studied
Interventions
- DEVICE EsoGuard
Study Locations (3)
Colorado
- ACUTE Center for Eating Disorders and Severe Malnutrition - Denver
- Denver Health and Hospital Authority - Denver
- Denver Health and Hospital Authority - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-11 |
What NCT06532734 shows while recruiting
NCT06532734 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (92% lower).
The record links to 6 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which EsoGuard is the first listed.
NCT06532734 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06532734 about?
NCT06532734 is a clinical study titled "Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype". To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors
What is the current status of trial NCT06532734?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-11-12. Estimated completion is 2026-11.
What conditions does trial NCT06532734 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Eating Disorders, Barrett Esophagus, Vomiting, Rumination.
What interventions are being tested in trial NCT06532734?
The interventions under investigation include: EsoGuard (DEVICE).
Who is sponsoring clinical trial NCT06532734?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532734 being conducted?
This trial has 3 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06532734's enrollment target sits among peer trials
25 36th of 43 higher than 8 of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI